BiotechTube
Phoenix Nest

Phoenix Nest

New York, United States· Est.
phoenixnestbiotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12.5M

Overview

Phoenix Nest is a private, pre-revenue biotech pioneering therapies for Sanfilippo syndrome, a fatal pediatric neurodegenerative disorder. Its pipeline includes gene therapy, enzyme replacement, and a neuroprotective peptide program, all supported by over $17 million in non-dilutive grants from the NIH and patient foundations. The company is characterized by a patient-founder ethos, a strong academic partnership network, and programs advancing through preclinical and early clinical study stages. Its mission is driven by an inherent sense of urgency to address these unmet medical needs.

Rare DiseaseNeurologyLysosomal Storage Disorders

Technology Platform

Multimodal therapeutic development engine focused on CNS delivery, including scAAV9 gene therapy, intracerebroventricular enzyme replacement, and intranasal neuroprotective peptides for Sanfilippo syndrome.

Funding History

2
Total raised:$12.5M
Series A$10M
Seed$2.5M

Opportunities

The complete lack of approved disease-modifying therapies for any Sanfilippo syndrome subtype presents a clear first-to-market opportunity.
Success in one program could validate the delivery platform (e.g., intrathecal AAV9) for application in other CNS disorders.
The strong NIH grant support validates the science and provides non-dilutive capital to reach key value-inflection points.

Risk Factors

High clinical risk associated with novel CNS delivery methods and demonstrating efficacy in a progressive neurodegenerative disease.
Financial risk due to dependence on grant funding for ongoing operations, with a future need for large capital to fund clinical trials.
Commercial risk is inherent in the ultra-orphan disease model, with a very small patient population.

Competitive Landscape

The Sanfilippo syndrome therapeutic landscape is sparse but includes a few other biotechs (e.g., Lysogene for MPS IIIA, Abeona Therapeutics for MPS IIIA/B) exploring gene and enzyme therapies, creating competition for patient recruitment and potential first-to-market status within subtypes. Phoenix Nest's focus on types C and D addresses less common subtypes with fewer active competitors, potentially offering a niche advantage.

More companies in Rare & Orphan Diseases →More companies in United States →